[Rosai-Dorfman disease: Diagnosis and therapeutic challenges]

Abstract

Rosai-Dorfman disease (RDD) was first described by the French pathologist Paul Destombes in 1965. It frequently affects children or young adults and is characterized by the presence of large histiocytes with emperipolesis. More than 50 years after this first description, the pathogenesis of this rare disease is still poorly understood. The revised classification of histiocytoses published in 2016 identified various forms of RDD, from familial RDD to IgG4-associated RDD. Almost 90% of the patients with RDD have cervical lymph nodes involvement although all the organs may virtually be involved. Outcomes are typically favorable. Treatments may be necessary in case of compression or obstruction, and are not well codified. The main therapeutic strategies rely on surgery, radiotherapy, steroids, immunosuppressive drugs or interferon-alpha and cladribine.

Keywords: Amyloidosis; Amylose; Histiocytose; Histiocytosis; Lymphadenopathy; Lymphadénopathie; Maladie de Rosai-Dorfman; Pachymenigitis; Pachyméningite; Rosai-Dorfman.